Showing 1291-1300 of 1484 results for "".
- Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code From the AMA for the Insertion of Intracanalicular Insertshttps://modernod.com/news/ocular-therapeutix-announces-receipt-of-a-permanent-category-i-cpt-code-from-the-ama-for-the-insertion-of-intracanalicular-inserts/2478492/Ocular Therapeutix announced that its application for the creation of a Category I Current Procedural Terminology (CPT) procedure code, presented at the October 2020 American Medical Association (AMA) CPT Editorial Panel meeting, has been granted. The Panel has accepted the addition of a permanen
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosahttps://modernod.com/news/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/2478365/Eyevensys announced that the FDA has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerat
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag
- Gyroscope Therapeutics Announces FDA Clearance of Orbit Subretinal Delivery Systemhttps://modernod.com/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/2478198/Gyroscope Therapeutics announced that the FDA has granted 510(k) clearance for the Orbit Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure
- Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targetshttps://modernod.com/news/pharma-company-exercises-rights-for-exclusive-use-of-everads-drug-delivery-technology-in-specific-retinal-targets/2478193/Everads Therapy has granted a pharmaceutical company a time-limited exclusivity for utilizing Everads’ suprachoroidal delivery technology for the development of specific ocular targets. In exchange for exclusivity of these specific ocular targets, Everads will receive a milestone payment. E
- Norlase Announces CE Mark Approval for LEAF Green Laserhttps://modernod.com/news/norlase-announces-ce-mark-approval-for-leaf-green-laser/2478045/Norlase announced that it has been granted the CE Mark approval for the LEAF, a first in class, fiberless green laser for the treatment of retina and glaucoma diseases. The CE Mark follows the recent FDA 510(k) market clearance of the LEAF and ISO 13485:2016 certification of Norlase’s medical dev
- National Vision Announces Special Cash Bonus to Front-Line Associates and Doctorshttps://modernod.com/news/national-vision-announces-special-cash-bonus-to-front-line-associates-and-doctors/2478032/National Vision Holdings announced plans to grant a special cash bonus to front-line associates and doctors. A one-time $250 bonus will be given to all patient-facing and customer-facing associates and the company’s network of doctors in recognition of their hard work and dedication toward
- BD Launches 15-minute Coronavirus Antigen Test, Promises Millions in Coming Monthshttps://modernod.com/news/bd-launches-15-minute-coronavirus-antigen-test-promises-millions-in-coming-months/2477994/The FDA granted an emergency authorization to a portable coronavirus antigen test developed by BD, similar to a rapid flu test, designed to allow hospitals, doctors’ offices, urgent care centers, and retail pharmacies to examine a person showing symptoms in about 15 minutes, accor
- Johnson & Johnson Vision Receives FDA Clearance for Catalys cOS 6.0 Software for Astigmatism Managementhttps://modernod.com/news/johnson-johnson-vision-recevies-fda-clearance-for-catalys-cos-6-0-software-for-astigmatism-management/2477915/The FDA has granted 510(k) clearance for new software for the Catalys Precision Laser System that aims to simplify astigmatism management workflow and increase operational efficiency. The Catalys cOS 6.0 software with advanced astigmatism management is a collaboration with Cassini Technolog
- Phosphorus Announces FDA Approval Of At-Home Saliva Test For COVID-19https://modernod.com/news/phosphorus-announces-fda-approval-of-at-home-saliva-test-for-covid-19/2477868/Phosphorus announced today that the FDA granted the Emergency Use Authorization request for its saliva test for COVID-19 that features at-home sample collection. The test is available by ordering online, as well as through health care and employer partnerships aimed at safely resuming operations.